Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease
Journal of Surgical Oncology2022Vol. 125(7), pp. 1176–1182
Citations Over TimeTop 10% of 2022 papers
Abstract
Gastric cancer (GC) is an aggressive malignancy with a high burden of peritoneal disease. Evidence regarding the use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) to improve outcomes has been growing. However, given multiple limitations, there remains a lack of international consensus regarding the optimal treatment paradigm. This review article discusses the burden of peritoneal disease in GC patients and the role of CRS + HIPEC in all treatment intents-curative, prophylactic, and palliative.
Related Papers
- → Systematic review of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian peritoneal carcinomatosis: A more efficacious way of delivering intraperitoneal chemotherapy(2009)4 cited
- Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis(2008)
- → Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for peritoneal carcinomatosis arising from ovarian cancer: our experience(2009)
- → 316. Cytoreductive Surgery and Hipertermy Intraperitoneal Chemoterapy in Patients with Peritoneal Carcinomatosis of Colonic Origin - Outcomes after 11 Years Experience(2012)
- → Mo1632 Readmission Following Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis – Can We Predict (or Avoid) Them?(2015)